Screener
Seres Therapeutics MCRB Q4 2025 Annual earnings
Reported March 12, 2026 · Before market open
Revenue$438.0KMiss by $4.9M
EPS-$1.89Beat by $0.50
Revenue estimate$5.3M
EPS estimate-$2.39
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$6.4M
EPS estimate-$1.01
Versus estimates
Revenue
Q2 2026$736.0KBeat by $557.0KQ1 2026$358.0KIn line
Q4 2025$438.0KMiss by $4.9M
Q3 2025$351.0KMiss by $7.5MDiluted EPS
FAQ
- When did Seres Therapeutics report Q4 2025 earnings?
- Seres Therapeutics (MCRB) reported Q4 2025 earnings on March 12, 2026 before market open.
- What were Seres Therapeutics's Q4 2025 revenue and EPS?
- Seres Therapeutics reported revenue of $438.0K and eps of $-1.89 for Q4 2025.
- Did Seres Therapeutics beat estimates in Q4 2025?
- Revenue missed the consensus estimate of $5.3M by $4.9M. EPS beat the consensus estimate of $-2.39 by $0.50.
- How did Seres Therapeutics's Q4 2025 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 490.6% from $-0.32.
- Where can I find Seres Therapeutics's Q4 2025 SEC filings?
- You can read the 8-K earnings release (0001193125-26-103034) and the 10-K periodic report (0001193125-26-103276) directly on SEC EDGAR. The filing index links above go to sec.gov.
